The China myasthenia gravis treatment market is anticipated to witness notable growth during the forecast period. Myasthenia gravis is an autoimmune neuromuscular disorder, which causes muscle weakness and tiredness. Rise in prevalence of myasthenia gravis cases in China coupled with positive reimbursement plans is expected to drive the market growth during the forecast period.
The key factor driving the growth of the China myasthenia gravis therapy market is increase in prevalence of myasthenia gravis in China. According to Statista, the prevalence of myasthenia gravis in China was estimated to be over 4,000 situations in 2019, and this number is expected to rise due to enhanced analysis abilities and recognition of the disease. This is anticipated to provide a massive demand for myasthenia gravis treatments. Furthermore, increase in R&D activities from the government of China and various health care organizations in the direction of guaranteeing the accessibility of various treatments is expected to augment the market growth.
In addition, the availability of different reimbursement plans by local, state, and national authorities is expected to be a crucial factor sustaining the growth of the market.
However, high cost associated with the diagnosis and treatment of myasthenia gravis is expected to be a significant factor limiting the growth of the China myasthenia gravis treatment market. Furthermore, availability of medicines of comparable effectiveness at more affordable rates is expected to hamper the market growth.
On the other hand, increase in focus of the market players on developing awareness regarding the disorder is expected to be a major factor to provide new avenues for the growth of the market. In addition, rise in federal government initiatives to promote the incorporation of new technologies in the field of medical diagnosis and treatment of myasthenia gravis is expected to fuel the growth of the China myasthenia gravis treatment market.
The China myasthenia gravis treatment market is expected to witness new trends in the upcoming years. This is attributed to shift from conventional treatment to advanced treatments such as monoclonal antibodies and intravenous immunoglobulin injections. In addition, increase in the number of collaborations between healthcare companies and scholastic institutes to establish new treatments for the condition is anticipated to provide lucrative opportunities for the growth of the market. Furthermore, the market players are focusing on advertising, marketing, and providing new service designs to increase their market share.
The China myasthenia gravis treatment market is expected to witness considerable growth due to the advancement of new products in the upcoming years. The businesses are focusing on introducing new treatments that provide effectiveness and long-lasting safety. Furthermore, businesses are focusing on research activities regarding the growth of new treatments that improve the lifestyle of people with myasthenia gravis. In addition, market players are focusing on creating consumer awareness about battling myasthenia gravis prevalence through different programs such as individual education and counseling.
Moreover, the market players are focusing on providing products with competitive rates in the market to increase the demand for their products. In addition, they are focused on creating new products which are cost-effective to make them available to more patients.
The Porter's five forces analysis is helpful to understand the market intensity of the China myasthenia gravis treatment market. It includes the bargaining power of buyers, the bargaining power of suppliers, the threat of substitutes, the threat of new entrants and the competition among competitive rivalry. The bargaining power of suppliers is moderate due to the existence of a few distributors in the market. The bargaining power of buyers is high due to upsurge in demand for new and economical treatments. The threat of new entrants is low due to the presence of a couple of big companies having a syndicate in the market. The threat of substitutes is moderate due to the availability of treatments for myasthenia gravis. The competitive rivalry between the existing market players is high due to the existence of a few huge companies.
The China myasthenia gravis treatment market is expected to witness significant growth in the upcoming years due to surge in prevalence of myasthenia gravis in China. Furthermore, government initiatives in campaigns for the advancement of new treatments, availability of reimbursement policies, and initiatives to promote consumer awareness regarding prevalence of myasthenia gravis are expected to be the major factor driving the market growth. However, the availability of medications of similar effectiveness at more affordable prices is expected to act as a key restraint for the market growth.
Key players included in the report are Nippon Boehringer Ingelheim, Yifan Pharmaceutical, Novartis, Shenzhen Salubris Pharmaceuticals, Shanghai Hainuo Bio Pharm, Shanghai Sanochemia Pharmaceuticals, Celgene Corporation, Pfizer, Gilead Sciences, Bayer AG.
The myasthenia gravis treatment market is segmented into drug class, and distribution channel. In terms of drug class, it is bifurcated into monoclonal antibodies, intravenous immunoglobulin, others. Based on the distribution channel, below 55 Years, above 55 Years.
The key factor driving the growth of the China myasthenia gravis therapy market is increase in prevalence of myasthenia gravis in China. According to Statista, the prevalence of myasthenia gravis in China was estimated to be over 4,000 situations in 2019, and this number is expected to rise due to enhanced analysis abilities and recognition of the disease. This is anticipated to provide a massive demand for myasthenia gravis treatments. Furthermore, increase in R&D activities from the government of China and various health care organizations in the direction of guaranteeing the accessibility of various treatments is expected to augment the market growth.
In addition, the availability of different reimbursement plans by local, state, and national authorities is expected to be a crucial factor sustaining the growth of the market.
However, high cost associated with the diagnosis and treatment of myasthenia gravis is expected to be a significant factor limiting the growth of the China myasthenia gravis treatment market. Furthermore, availability of medicines of comparable effectiveness at more affordable rates is expected to hamper the market growth.
On the other hand, increase in focus of the market players on developing awareness regarding the disorder is expected to be a major factor to provide new avenues for the growth of the market. In addition, rise in federal government initiatives to promote the incorporation of new technologies in the field of medical diagnosis and treatment of myasthenia gravis is expected to fuel the growth of the China myasthenia gravis treatment market.
The China myasthenia gravis treatment market is expected to witness new trends in the upcoming years. This is attributed to shift from conventional treatment to advanced treatments such as monoclonal antibodies and intravenous immunoglobulin injections. In addition, increase in the number of collaborations between healthcare companies and scholastic institutes to establish new treatments for the condition is anticipated to provide lucrative opportunities for the growth of the market. Furthermore, the market players are focusing on advertising, marketing, and providing new service designs to increase their market share.
The China myasthenia gravis treatment market is expected to witness considerable growth due to the advancement of new products in the upcoming years. The businesses are focusing on introducing new treatments that provide effectiveness and long-lasting safety. Furthermore, businesses are focusing on research activities regarding the growth of new treatments that improve the lifestyle of people with myasthenia gravis. In addition, market players are focusing on creating consumer awareness about battling myasthenia gravis prevalence through different programs such as individual education and counseling.
Moreover, the market players are focusing on providing products with competitive rates in the market to increase the demand for their products. In addition, they are focused on creating new products which are cost-effective to make them available to more patients.
The Porter's five forces analysis is helpful to understand the market intensity of the China myasthenia gravis treatment market. It includes the bargaining power of buyers, the bargaining power of suppliers, the threat of substitutes, the threat of new entrants and the competition among competitive rivalry. The bargaining power of suppliers is moderate due to the existence of a few distributors in the market. The bargaining power of buyers is high due to upsurge in demand for new and economical treatments. The threat of new entrants is low due to the presence of a couple of big companies having a syndicate in the market. The threat of substitutes is moderate due to the availability of treatments for myasthenia gravis. The competitive rivalry between the existing market players is high due to the existence of a few huge companies.
The China myasthenia gravis treatment market is expected to witness significant growth in the upcoming years due to surge in prevalence of myasthenia gravis in China. Furthermore, government initiatives in campaigns for the advancement of new treatments, availability of reimbursement policies, and initiatives to promote consumer awareness regarding prevalence of myasthenia gravis are expected to be the major factor driving the market growth. However, the availability of medications of similar effectiveness at more affordable prices is expected to act as a key restraint for the market growth.
Key players included in the report are Nippon Boehringer Ingelheim, Yifan Pharmaceutical, Novartis, Shenzhen Salubris Pharmaceuticals, Shanghai Hainuo Bio Pharm, Shanghai Sanochemia Pharmaceuticals, Celgene Corporation, Pfizer, Gilead Sciences, Bayer AG.
The myasthenia gravis treatment market is segmented into drug class, and distribution channel. In terms of drug class, it is bifurcated into monoclonal antibodies, intravenous immunoglobulin, others. Based on the distribution channel, below 55 Years, above 55 Years.
Key Benefits For Stakeholders
- Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.
- Analyze the key strategies adopted by major market players in China Myasthenia Gravis treatment market.
- Assess and rank the top factors that are expected to affect the growth of China Myasthenia Gravis treatment market.
- Top Player positioning provides a clear understanding of the present position of market players.
- Identify key investment pockets for various offerings in the market.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Product Benchmarking / Product specification and applications
- Upcoming/New Entrant by Regions
- Patient/epidemiology data at country, region, global level
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- SWOT Analysis
Key Market Segments
By Age group
- Below 55 years
- Above 55 years
By Drug class
- Monoclonal antibodies
- Intravenous immunoglobulin
- Others
By Distribution channel
- Hospital pharmacies
- Drug store and retail pharmacies
- Online providers
- Key Market Players
- Nippon Boehringer Ingelheim
- Yifan Pharmaceutical
- Novartis
- Shenzhen Salubris Pharmaceuticals
- Shanghai Hainuo Bio Pharm
- Shanghai Sanochemia Pharmaceuticals
- Celgene Corporation
- Pfizer
- Gilead Sciences
- Bayer AG
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: CHINA MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS
CHAPTER 5: CHINA MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP
CHAPTER 6: CHINA MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
CHAPTER 7: COMPETITIVE LANDSCAPE
CHAPTER 8: COMPANY PROFILES
List of Tables
List of Figures
Companies Mentioned
- Nippon Boehringer Ingelheim
- Yifan Pharmaceutical
- Novartis
- Shenzhen Salubris Pharmaceuticals
- Shanghai Hainuo Bio Pharm
- Shanghai Sanochemia Pharmaceuticals
- Celgene Corporation
- Pfizer
- Gilead Sciences
- Bayer AG
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
